Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Neurology International|January 22, 2021
Telemedicine during the Coronavirus Disease (COVID-19) Pandemic: A Multiple Sclerosis (MS) Outpatients Service PerspectiveFrancesco Corea, Silvia Ciotti, Antonella Cometa, et al.European Journal of Case Reports in Internal Medicine|March 26, 2021
Neurofibromatosis Type 1 with Highly Active Relapsing-Remitting Multiple Sclerosis (RRMS)Silvia Ciotti, Antonella Cometa, Claudia De Carlo, et al.Journal of Alzheimer'S Disease : JAD|January 11, 2012
Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairmentLucilla Parnetti, Davide Chiasserini, Paolo Eusebi, et al.European Journal of Case Reports in Internal Medicine|October 21, 2021
Treatment with Delta-9-tetrahydrocannabinol/cannabidiol in Multiple Sclerosis: Influence on the Autonomy Profile according to the International Classification of Functioning, Disability and HealthSilvia Ciotti, Mary Micheli, Antonella Cometa, et al.Frontiers in Aging Neuroscience|April 19, 2014
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's DiseaseLucilla Parnetti, Lucia Farotti, Paolo Eusebi, et al.Plos One|July 2, 2014
Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluidEmanuele Persichetti, Davide Chiasserini, Lucilla Parnetti, et al.Movement Disorders : Official Journal of the Movement Disorder Society|April 7, 2011
Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementiasLucilla Parnetti, Davide Chiasserini, Gianni Bellomo, et al.Movement Disorders : Official Journal of the Movement Disorder Society|January 18, 2014
Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's diseaseLucilla Parnetti, Davide Chiasserini, Emanuele Persichetti, et al.Pageof 1